Effective Product Control

por Nash, Peter
Publicado 2017

Clinical use of Jak 1 inhibitors for rheumatoid arthritis

por Nash, Peter
Publicado 2021

Telemedicine and rheumatology

por Nash, Peter
Publicado 2022

Choosing the right treatment for patients with psoriatic arthritis

por Noviani, Maria, Feletar, Marie, Nash, Peter, Leung, Ying Ying
Publicado 2020

The Effect of Etanercept in Nonradiographic Axial Spondyloarthritis by Stratified C‐Reactive Protein Levels

por Tam, Hoi Ki Joshua, Nash, Peter, Robinson, Philip C.
Publicado 2021

Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease Mechanisms

por Tam, Hoi Ki Joshua, Robinson, Philip C., Nash, Peter
Publicado 2022

Long-Term Safety of Subcutaneous Abatacept in Rheumatoid Arthritis: Integrated Analysis of Clinical Trial Data Representing More Than Four Years of Treatment

por Alten, Rieke, Kaine, Jeffrey, Keystone, Edward, Nash, Peter, Delaet, Ingrid, Genovese, Mark C
Publicado 2014

Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib

por Bird, Paul, Hall, Stephen, Nash, Peter, Connell, Carol A, Kwok, Kenneth, Witcombe, David, Thirunavukkarasu, Krishan
Publicado 2019

Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and pr...

por Nash, Peter, Behrens, Frank, Orbai, Ana-Maria, Rathmann, Suchitrita S, Adams, David H, Benichou, Olivier, Deodhar, Atul
Publicado 2018

Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data

por Bykerk, Vivian P., Nash, Peter, Nicholls, David, Tanaka, Yoshiya, Winthrop, Kevin, Popova, Christina, Tilt, Nicola, Haaland, Derek
Publicado 2023

Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials

por Kivitz, Alan J., FitzGerald, Oliver, Nash, Peter, Pang, Shirley, Azevedo, Valderilio F., Wang, Cunshan, Takiya, Liza
Publicado 2021

The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2

por Deodhar, Atul, Gladman, Dafna, Bolce, Rebecca, Sandoval, David, Park, So Young, Leage, Soyi Liu, Nash, Peter, Poddubnyy, Denis
Publicado 2023

Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis

por Nash, Peter, Vanhoof, Johan, Hall, Stephen, Arulmani, Udayasankar, Tarzynski-Potempa, Rita, Unnebrink, Kristina, Payne, Andrew N., Cividino, Alfred
Publicado 2016

Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis

por Gladman, Dafna, Nash, Peter, Goto, Hitoshi, Birt, Julie A, Lin, Chen-Yen, Orbai, Ana-Maria, Kvien, Tore K
Publicado 2020

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)

por Nash, Peter, Ohson, Kamal, Walsh, Jessica, Delev, Nikolay, Nguyen, Dianne, Teng, Lichen, Gómez-Reino, Juan J, Aelion, Jacob A
Publicado 2018

The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies

por Bingham, Clifton O., Walker, David, Nash, Peter, Lee, Susan J., Ye, Lei, Hu, Hao, Khalid, Javaria Mona, Combe, Bernard
Publicado 2022

Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes

por Nash, Peter, Dutz, Jan P, Peterson, Steve, Patel, Barkha P, Eaton, Kiefer, Shawi, May, Zazzetti, Federico, Wei, James Cheng-Chung
Publicado 2023

Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population

por Hall, Stephen, Nash, Peter, Rischmueller, Maureen, Bossingham, David, Bird, Paul, Cook, Nicola, Witcombe, David, Soma, Koshika, Kwok, Kenneth, Thirunavukkarasu, Krishan
Publicado 2018

Correction to: Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT...

por Coates, Laura C., Mease, Philip, Kronbergs, Andris, Helt, Cameron, Sandoval, David, Park, So Young, Combe, Bernard, Nash, Peter, Deodhar, Atul
Publicado 2022

Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-...

por Coates, Laura C., Mease, Philip, Kronbergs, Andris, Helt, Cameron, Sandoval, David, Park, So Young, Combe, Bernard, Nash, Peter, Deodhar, Atul
Publicado 2022